Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients With Operable Pancreatic Adenocarcinoma
研究概览
详细说明
This is a single arm, non-randomized phase II study. Eligible, fully registered patients will receive preoperative chemotherapy consisting of gemcitabine plus erlotinib. Preoperative chemotherapy will be followed by exploratory laparotomy and pancreaticoduodenectomy. Patients will then receive postoperative chemotherapy consisting of gemcitabine plus erlotinib. Up to 123 patients will be accrued to this study, with the expectation that 78 patients will remain fully eligible and evaluable for the primary endpoint. The primary and secondary objectives for the study are listed below.
Primary Objective:
To estimate the proportion of patients alive at two years from the date of registration
Secondary Objectives:
- To determine the resection rate (defined as the fraction of patients who proceed to planned surgery with removal of primary tumor [R0/R1]) following induction treatment with gemcitabine plus erlotinib
- To estimate the time to disease progression/relapse
- To evaluate the rate of R0, R1, and R2 resections (defined as per the 6th edition of the AJCC Cancer Staging Manual) in patients treated with preoperative gemcitabine plus erlotinib chemotherapy
- To evaluate the toxicity profile of preoperative gemcitabine plus erlotinib and the feasibility of postoperative gemcitabine plus erlotinib
- To evaluate response rates to preoperative chemotherapy for patients treated with preoperative gemcitabine and erlotinib
- To identify molecular predictors of pancreatic cancer response to gemcitabine combined with erlotinib
- To identify genetic profiles of pancreatic adenocarcinoma that may be associated with response to neoadjuvant therapy
After completion of postoperative chemotherapy treatment, patients are followed every 3 months for 2 years and then every 6 months for 2 years.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 2M9
- Princess Margaret Hospital
-
-
-
-
California
-
La Jolla、California、美国、92093-0658
- Rebecca and John Moores UCSD Cancer Center
-
Los Angeles、California、美国、90027
- Kaiser Permanente Medical Center - Los Angeles
-
Orange、California、美国、92868
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
-
-
Connecticut
-
Bridgeport、Connecticut、美国、06606
- St. Vincent's Medical Center
-
-
Florida
-
Lakeland、Florida、美国、33805
- Lakeland Regional Cancer Center at Lakeland Regional Medical Center
-
-
Indiana
-
Indianapolis、Indiana、美国、46237
- St. Francis Hospital Cancer Care Services
-
-
Maryland
-
Baltimore、Maryland、美国、21229
- St. Agnes Hospital Cancer Center
-
Baltimore、Maryland、美国、21215
- Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
-
-
Mississippi
-
Jackson、Mississippi、美国、39216
- University of Mississippi Cancer Clinic
-
-
Nebraska
-
Omaha、Nebraska、美国、68114
- Methodist Estabrook Cancer Center
-
-
New York
-
New York、New York、美国、10016
- NYU Cancer Institute at New York University Medical Center
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27599-7295
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
-
-
Ohio
-
Dayton、Ohio、美国、45409
- David L. Rike Cancer Center at Miami Valley Hospital
-
Dayton、Ohio、美国、45415
- Samaritan North Cancer Care Center
-
Dayton、Ohio、美国、45420
- CCOP - Dayton
-
Kettering、Ohio、美国、45429
- Charles F. Kettering Memorial Hospital
-
Troy、Ohio、美国、45373-1300
- UVMC Cancer Care Center at Upper Valley Medical Center
-
-
Oklahoma
-
Tulsa、Oklahoma、美国、74136
- Natalie Warren Bryant Cancer Center at St. Francis Hospital
-
-
Oregon
-
Portland、Oregon、美国、97213-2967
- Providence Cancer Center at Providence Portland Medical Center
-
-
South Carolina
-
Spartanburg、South Carolina、美国、29303
- Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
-
-
Virginia
-
Newport News、Virginia、美国、23606
- Surgical Oncology Associates
-
-
West Virginia
-
Morgantown、West Virginia、美国、26506
- Mary Babb Randolph Cancer Center at West Virginia University Hospitals
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792-6164
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Eligibility Criteria:
Cytologic or histologic proof of adenocarcinoma of the pancreatic head or uncinate process.
NOTE: Patients with tumors of the pancreatic neck, body or tail are not eligible. Patients with evidence of neuroendocrine tumors, duodenal adenocarcinoma, or ampullary adenocarcinoma are not eligible.
Localized, potentially resectable tumors as defined below. All patients must be staged with a chest X-ray or CT, and abdominal CT (contrast-enhanced, helical thin-cut) or MRI. Radiological resectability is defined by the following criteria on abdominal imaging:
- No evidence of tumor extension to the celiac axis, hepatic artery, or superior mesenteric artery
- No evidence of tumor encasement or occlusion of the superior mesenteric vein (SMV) or the SMV/portal vein confluence
- No evidence of visceral or peritoneal metastases
NOTE: Patients with borderline resectable or marginally resectable pancreatic cancer are not eligible. Patients must meet all objective imaging criteria outlined above.
- ≥ 18 years of age
- ECOG/Zubrod performance status of 0 or 1
- Baseline weight loss ≤ 15% of premorbid weight
Patient must have adequate hematologic, renal, and hepatic function as defined by:
- WBC ≥ 2,000 cells/mm³
- ANC ≥ 1,500 cells/mm³
- Platelets ≥ 100,000 cells/mm³
- Serum bilirubin ≤ 2.5 mg/dL
- Serum creatinine ≤ 1.5 mg/dL or a calculated creatinine clearance of ≥ 50 ml/min (24 hour urine collection)
- ALT < 2.5 times upper limit of normal (ULN)
- AST < 2.5 times ULN
- Albumin ≥ 3.2 g/dl
No history of the following:
- Prior EGFR targeted therapy or therapy for pancreatic cancer
- Active infection requiring intravenous antibiotics at the time of registration
- Non-pregnant and non-breast feeding. Female participants of child bearing potential must have a negative urine or serum pregnancy test prior to registration. Perimenopausal participants must be amenorrheic ≥ 12 months to be considered not of childbearing potential. All patients of reproductive potential must agree to use an effective method of birth control while receiving study therapy.
- No prior malignancy within 5 years of registration (Exceptions: non-melanoma skin cancer, in-situ cancers)
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Neoadjuvant therapy + Surgery + Adjuvant therapy
As part of neoadjuvant therapy, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 29, 36, and 43 and oral erlotinib hydrochloride once daily on days 1-43 in the absence of disease progression or unacceptable toxicity.
Within 3-6 weeks after completion of neoadjuvant therapy, patients undergo pancreaticoduodenectomy and patients receive gemcitabine hydrochloride and erlotinib hydrochloride as in neoadjuvant therapy within 5-10 weeks post surgery.
|
oral administration
Intravenous administration
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Survival at 2 Years
大体时间：At 2 years post-registration
|
The primary endpoint of this trial is 2-year overall survival, which will be evaluated as the proportion of treatment successes.
A treatment success is defined to be an evaluable patient who is alive at two years from the date of registration.
|
At 2 years post-registration
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Resection Rate
大体时间：Up to 4 years postoperative chemotherapy treatment
|
The resection rate is defined as the fraction of patients that proceed to planned surgery with removal of primary tumor (R0/R1) following neoadjuvant treatment with gemcitabine plus erlotinib.The resection rate will be estimated by the binomial point estimate, i.e. as the number of patients that undergo the planned surgery with removal of the primary tumor following neoadjuvant treatment with gemcitabine plus erlotinib divided by the number of evaluable patients. This quantity will also be estimated with a 95% binomial confidence interval. Curative resection (R0) is defined as macroscopically and microscopically complete resection (with microscopic surgical margin assessment according to AJCC Staging Principles). An R1 resection is defined as macroscopically complete tumor removal with any positive microscopic surgical margin (bile duct, pancreatic parenchyma, or SMA margins). |
Up to 4 years postoperative chemotherapy treatment
|
|
Relapse/Progression-free Survival
大体时间：At 2 years post-registration
|
Relapse/progression-free survival is defined as the time from date of registration to the date of documentation of disease recurrence/progression.
If a patient dies without documentation of disease recurrence/progression, the patient will be considered to have had disease recurrence/progression at the time of their death unless there is sufficient documented evidence to conclude no recurrence/progression occurred prior to death.
If a patient is declared to be a major treatment violation, the patient will be censored on the date the treatment violation occurred.
If a patient is lost to follow-up, s/he will be censored at the data of last contact.
The distribution of disease-free survival will be estimated using the method of Kaplan and Meier.
|
At 2 years post-registration
|
|
Number of Participants Experiencing Grade 3 or Higher Adverse Events as Graded by the NCI's Common Toxicity Criteria for Adverse Events
大体时间：Up to 4 years postoperative chemotherapy treatment
|
The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine adverse event patterns.
These patterns will be summarized with descriptive statistics.
The number of patients reporting grade 3 or higher adverse events as graded by the NCI's Common Toxicity Criteria (CTCAE) Version 4 are reported here.
A complete list of all reported adverse events is reported in the Adverse Events section of this report.
|
Up to 4 years postoperative chemotherapy treatment
|
|
Response Rate
大体时间：Up to 4 years postoperative chemotherapy treatment
|
The response rates to preoperative chemotherapy for patients treated with preoperative gemcitabine and erlotinib and rates of accurate pathologic assessment of the resected tumor specimen according to College of American Pathology guidelines will be estimated with a binomial point estimate and corresponding 95% confidence intervals.
|
Up to 4 years postoperative chemotherapy treatment
|
合作者和调查者
调查人员
- 学习椅：Peter W.T. Pisters, MD、M.D. Anderson Cancer Center
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- ACOSOG-Z5041
- U10CA076001 (美国 NIH 拨款/合同)
- NCI-2009-00348 (其他标识符：NCI Clinical Trial Reporting Office)
- CDR0000609871 (注册表标识符：NCI Physician Data Query)
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.